1515 Results
Sort By:
Published on July 1, 2019
Researchers have developed a test that predicts the likelihood that a person with invasive lobular breast cancer (ILC) will benefit from chemotherapy. The findings were published in the June 27, 2019 issue of Nature Partner Journals Breast Cancer, a joint publication between Nature and the Breast Cancer Research Foundation. “In this…
Published on June 26, 2019
Researchers have uncovered three ways FOXA1 (Forkhead box A1) gene mutations override normal biology to drive an estimated one-third of prostate cancers. Dubbed FAST, FURIOUS and LOUD, the three mechanisms are described in a paper by researchers at the University of Michigan Rogel Cancer Center. Their findings were published in Nature,…
Published on June 24, 2019
IsoPlexis has won a $4 million grant from the National Cancer Institute (NCI)’s Small Business Innovation Research (SBIR) Development Center toward commercializing its IsoLight single-cell, secreted protein analysis system. Based in Branford, CT, IsoLight is a precision engineering platform designed for research use only in CAR-T therapy product evaluation, quality…
Published on June 14, 2019
For some time, gut microbes have been thought to metabolize and lessen the efficacy of levodopa, the primary drug treatment for Parkinson’s disease, but the species responsible have eluded detection. One such species, however, was recently identified by scientists based at Harvard University. Combing through data from the Human Microbiome…
Published on June 12, 2019
By Cindy Perettie, CEO, Foundation Medicine The way ASCO started for me this year set the scene for what was an inspiring and fascinating weekend. Early on Friday morning, before most people’s ASCOs had started, I sat in a meeting room in the conference center watching it slowly fill to…
Published on June 3, 2019
In the first Phase III trial ever to test maintenance treatment with a PARP inhibitor in pancreatic cancer, patients with germline BRCA1 or BRCA2 mutations showed significantly improved progression free survival (PFS) on the PARP inhibitor Lynparza (olaparib) versus placebo. These findings come of the heels of the National Comprehensive…
Published on May 30, 2019
The possibility of metabolomics playing a role in cancer diagnostics and treat- ment seems, to many metabolomicists, a question of when rather than if. After all, metabolomics is a powerful platform to measure the endpoint of human physiology—a direct readout of physiological changes—and is easily sampled in blood. Despite its…
Published on May 16, 2019
Nearly one-quarter (24%) of the 422 patients screened in the Pediatric Molecular Analysis for Therapy Choice (Pediatric MATCH) trial are eligible for treatment with at least one drug being tested in the study, the National Cancer Institute (NCI) and the NCI-supported Children’s Oncology Group (COG) said. That’s more than double…
Published on May 6, 2019
DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful with respect to another important task—the selection of the best…
Published on April 29, 2019
Colon cancer ranks third in prevalence and fourth in cancer deaths among all cancers worldwide. However, due to its extreme heterogeneity, progress has been slow towards precision diagnostics and treatments. The National Cancer Institute’s Proteomic Tumor Analysis Consortium, led by researchers at Baylor College of Medicine, embarked upon a mission…
Published on April 18, 2019
Statistics can be a great tool for analyzing datasets and it can also be a sobering means to provide a stark reality. For instance, recent data suggests that approximately every three minutes one person in the United States is diagnosed with some form of blood cancer. While this statistic shows…
Published on April 10, 2019
A study published yesterday in Journal of the American Medical Association offers validation that real-world data obtained from routine clinical care to generate a multi-institution clinico-genomic database is feasible and can yield novel, clinically meaningful insights, Foundation Medicine and Flatiron Health said. Researchers from the two Roche subsidiaries joined collaborators…
Published on April 4, 2019
It is widely appreciated that sex differences play a role in both the incidence of and treatment outcomes of many diseases, including some cancers. New research provides an understanding of this phenomenon for glioblastoma (GBM), the most common malignant brain tumor, through the identification of sex-specific molecular pathways. This work…
Published on April 2, 2019
In 2013, much of the world was introduced to the burgeoning field of precision medicine when world-famous actress, Angelina Jolie, announced she had undergone a double mastectomy to reduce her chances of getting breast cancer. With that announcement, things like BRCA genes, mutations, and proteins were thrust onto the public…
Published on March 29, 2019
Molecular diagnostic company ArcherDX announced it has entered into a research collaboration with the University College London (UCL) and the Francis Crick Institute to use ArcherDX’s proprietary Anchored Multiplex PCR (AMP) technology to detect evidence of disease recurrence in lung cancer patients using cell-free circulating tumor DNA (ctDNA). The research…